Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
ddp created	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
ddp modified
hansard heading
house id
identifier
legislature	pref label
parliament number
question first answered
question text
session
session number
tabling member constituency
tabling member printed
title
type
uin
version
written parliamentary question type
answer	is ministerial correction true false question first answered
creator	label
publisher	pref label
tabling member	label

Search

1001918

	human indexable
	published
	registered interest
	answer date	12/11/2018
	date	05/11/2018
	date tabled	05/11/2018
	ddp created	05/11/2018 22:16:21
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	05/11/2018 22:35:43 14/11/2018 11:53:01
	hansard heading	Rare Diseases: Drugs
	house id	1
	identifier	188233
	legislature	25259 pref label House of Commons
	parliament number	57
	question first answered	14/11/2018 11:21:33
	question text	To ask the Secretary of State for Health and Social Care, whether officials in his Department have had discussions with the Scottish Government on the (a) Patient and Clinician Engagement system, (b) its effect on approval rates for new rare disease medicines in Scotland and (c) potential lessons from that system for NHS England.
	session	2017/19
	session number	1
	tabling member constituency	Bury North
	tabling member printed	James Frith
	title	House of Commons Tabled Parliamentary Question 2017/19 188233
	type	WrittenParliamentaryQuestion
	uin	188233
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction question first answered 14/11/2018 11:21:33
	creator	4637 label Biography information for James Frith
	publisher	25259 pref label House of Commons
	tabling member	4637 label Biography information for James Frith

1001919

	human indexable
	published
	registered interest
	answer date	12/11/2018
	date	05/11/2018
	date tabled	05/11/2018
	ddp created	05/11/2018 22:16:23
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	05/11/2018 22:35:45 12/11/2018 17:55:02
	hansard heading	Rare Diseases: Drugs
	house id	1
	identifier	188234
	legislature	25259 pref label House of Commons
	parliament number	57
	question first answered	12/11/2018 17:23:30
	question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 4.12 the UK Rare Diseases Strategy, what assessment his Department has made of whether the National Institute for Health and Care Excellence’s Single Technology Appraisal Programme meets the ambition of suitability for assessing rare disease treatments.
	session	2017/19
	session number	1
	tabling member constituency	Bury North
	tabling member printed	James Frith
	title	House of Commons Tabled Parliamentary Question 2017/19 188234
	type	WrittenParliamentaryQuestion
	uin	188234
	version	1
	written parliamentary question type	NamedDay
	answer	answer is ministerial correction question first answered 12/11/2018 17:23:30
	creator	4637 label Biography information for James Frith
	publisher	25259 pref label House of Commons
	tabling member	4637 label Biography information for James Frith